Adverum Biotechnologies
在场
Adverum Biotechnologies 是一家在股票代码 ADVM (US) 下上市的公司。
高管
查看带有其 24 名主要高管的组织结构图
Adverum Biotechnologies 搜索最多的简介
- Laurent Fischer, President, Chief Executive Officer and Interim Ch...
- Patrick Machado, Chairman of the Board
- James Scopa, Director
高管在Adverum Biotechnologies变化
- Jason Mitchell已作为Chief Commercial Officer加入公司 (新闻发布的2024十月17号).
- Szilárd Kiss已作为Director加入公司 (新闻发布的2024六月12号).
- Rabia Gurses Ozden 曾任 Director, 现升职为 Chief Medical Officer (新闻发布的2024六月12号).
创建提醒
跟踪 Adverum Biotechnologies 的高管变动
生物技术
Adverum Biotechnologies 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Adverum Biotechnologies 的最新新闻稿
- Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
- Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
- Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
- Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
- Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
- Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
- Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
- View more press releases Close
通过电子邮件
